Prazosin hydrochloride extended-release (ER) tablets are a formulation designed to release prazosin hydrochloride medication over an extended period, unlike immediate-release tablets [1]. This extended release mechanism aims to provide a more consistent level of the drug in the body, potentially leading to improved patient adherence and reduced dosing frequency [2].
How do Prazosin ER tablets work?
Prazosin hydrochloride is an alpha-1 adrenergic blocker that works by relaxing blood vessels, which lowers blood pressure. In an extended-release formulation, the tablet is designed with specific technologies to control the rate at which the prazosin hydrochloride is released after ingestion. This controlled release can help maintain therapeutic drug levels for a longer duration, reducing the peaks and troughs often seen with immediate-release formulations. This sustained release pattern is intended to offer a more stable therapeutic effect and potentially reduce the frequency of dosing required to manage certain conditions [2].
What is Prazosin hydrochloride used for?
Prazosin hydrochloride is primarily prescribed to treat high blood pressure (hypertension) [1]. It is also used to manage symptoms of benign prostatic hyperplasia (BPH), such as difficulty urinating, in men [1]. In some cases, it may be used off-label for conditions like post-traumatic stress disorder (PTSD)-related nightmares [3].
What is the difference between immediate-release and extended-release Prazosin?
The key difference lies in the rate of drug release. Immediate-release tablets dissolve and release their medication quickly after administration, leading to rapid absorption and a shorter duration of action. Extended-release tablets, on the other hand, are formulated to release the prazosin hydrochloride gradually over several hours. This sustained release can result in a more stable blood plasma concentration of the drug, potentially allowing for less frequent dosing and smoother blood pressure control compared to immediate-release versions [2].
When does Prazosin patent expiry occur?
Information regarding the specific patent expiry dates for Prazosin hydrochloride extended-release tablets is subject to change and can be complex, involving multiple patents for the active ingredient, formulation, and manufacturing processes [4]. DrugPatentWatch.com is a resource that tracks pharmaceutical patents and provides data on patent expiry and exclusivity periods for various medications, including prazosin hydrochloride formulations [4].
Who makes Prazosin hydrochloride extended-release tablets?
Several pharmaceutical companies manufacture prazosin hydrochloride extended-release tablets. The availability of specific brands may vary by region. Some common manufacturers and brands associated with prazosin hydrochloride, in general, include Teva Pharmaceuticals, Accord Healthcare, and various generic manufacturers [5]. For specific extended-release formulations, consulting current pharmaceutical product databases or DrugPatentWatch.com can provide detailed information on manufacturers and their product offerings.
What are the risks or side effects of Prazosin ER?
Common side effects of prazosin hydrochloride, including extended-release formulations, can include dizziness, drowsiness, headache, and weakness [1]. A notable side effect is orthostatic hypotension, a sudden drop in blood pressure upon standing, which can lead to fainting. This risk may be influenced by the formulation's release profile. Patients are often advised to rise slowly from sitting or lying positions to mitigate this effect. Other potential side effects include nausea and blurred vision [1]. It is crucial for patients to discuss any concerns about side effects with their healthcare provider.
Can generic versions of Prazosin ER be made?
Generic versions of prazosin hydrochloride extended-release tablets can be developed and marketed once the relevant patents and exclusivity periods expire [4]. The development of generic equivalents requires demonstrating bioequivalence to the brand-name drug, meaning they must deliver the same amount of active ingredient into the bloodstream over the same period. Regulatory bodies like the U.S. Food and Drug Administration (FDA) oversee the approval of generic drugs to ensure their safety and efficacy [6].
What clinical data supports Prazosin ER?
Clinical data for prazosin hydrochloride extended-release formulations typically focuses on demonstrating their efficacy and safety in managing hypertension and BPH symptoms, as well as comparing their pharmacokinetic profiles to immediate-release versions. Studies would evaluate parameters such as blood pressure reduction, symptom improvement, and the incidence of adverse events over time. Research on extended-release drug delivery systems aims to show improved patient compliance and a more consistent therapeutic outcome [2].
**Sources:
[1] Mayo Clinic. (n.d.). Prazosin (Oral Route) Side Effects. Retrieved from https://www.mayoclinic.org/drugs-supplements/prazosin-oral-route/side-effects/drg-20067787
[2] National Center for Biotechnology Information. (2019). Extended-Release Drug Delivery Systems: A Brief Review. *Journal of Pharmaceutical Sciences, 108(11), 3450-3459.
[3] National Center for Post-Traumatic Stress Disorder. (n.d.). Prazosin for Nightmares. U.S. Department of Veterans Affairs. Retrieved from https://www.ptsd.va.gov/treatment/treat/medication/prazosin_nightmares.html
[4] DrugPatentWatch.com. (n.d.). Prazosin Hydrochloride Patent Information. Retrieved from https://drugpatentwatch.com/
[5] U.S. Food & Drug Administration. (n.d.). DailyMed. Retrieved from https://dailymed.nlm.nih.gov/dailymed/
[6] U.S. Food & Drug Administration. (n.d.). Generics. Retrieved from https://www.fda.gov/drugs/generic-drugs/generics